| Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a … V Poeschel, G Held, M Ziepert, M Witzens-Harig, H Holte, L Thurner, ... The Lancet 394 (10216), 2271-2281, 2019 | 215 | 2019 |
| IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination L Thurner, C Kessel, N Fadle, E Regitz, F Seidel, I Kindermann, S Lohse, ... New England Journal of Medicine 387 (16), 1524-1527, 2022 | 60 | 2022 |
| Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky … M Pfreundschuh, K Christofyllakis, B Altmann, M Ziepert, M Haenel, ... Journal of Clinical Oncology 35 (15_suppl), 7506-7506, 2017 | 42 | 2017 |
| Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper NR Neuendorff, KP Loh, AS Mims, K Christofyllakis, WK Soo, B Bölükbasi, ... Blood advances 4 (4), 762-775, 2020 | 41 | 2020 |
| Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical … K Christofyllakis, JT Bittenbring, L Thurner, M Ahlgrimm, S Stilgenbauer, ... Molecular and Clinical Oncology 16 (1), 21, 2022 | 32 | 2022 |
| Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B-cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of rituximab … V Poeschel, G Held, M Ziepert, B Altmann, M Witzens-Harig, H Holte, ... Blood 132, 781, 2018 | 26 | 2018 |
| Adjuvant therapy of high-risk (Stages IIC–IV) malignant melanoma in the post interferon-alpha era: a systematic review and meta-analysis K Christofyllakis, C Pföhler, M Bewarder, CSL Müller, L Thurner, ... Frontiers in Oncology 10, 637161, 2021 | 24 | 2021 |
| Autoantibodies against Progranulin and IL-1 receptor antagonist in critically ill COVID-19 L Thurner, N Fadle, M Bewarder, I Kos, E Regitz, O Cetin, B Thurner, ... | 13* | 2021 |
| Management of extranodal marginal zone lymphoma: present and upcoming perspectives D Kaddu-Mulindwa, L Thurner, K Christofyllakis, M Bewarder, IA Kos Cancers 14 (12), 3019, 2022 | 10 | 2022 |
| Excellent outcome of elderly patients with favourable-prognosis DLBCL treated with 4 cycles CHOP/Chlip-14 plus 8 applications of rituximab and a PET-based intensification … M Pfreundschuh, N Murawski, K Christofyllakis, B Altmann, M Ziepert, ... Blood 130, 1549, 2017 | 9 | 2017 |
| Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019 V Lesan, M Bewarder, C Metz, A Becker, S Mang, E Regitz, L Thurner, ... Intensive Care Medicine Experimental 9, 1-10, 2021 | 8 | 2021 |
| Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients … M Pfreundschuh, K Christofyllakis, B Altmann, M Ziepert, M Haenel, ... Oncol. Res. Treat. 40, 11-12, 2017 | 8 | 2017 |
| The b-cell receptor autoantigen LRPAP1 can replace variable antibody regions to target mantle cell lymphoma cells M Bewarder, M Kiefer, H Will, K Olesch, C Moelle, S Stilgenbauer, ... HemaSphere 5 (8), e620, 2021 | 7 | 2021 |
| Integration of the B-cell receptor antigen Neurabin-I/SAMD14 into an antibody format as new therapeutic approach for the treatment of primary CNS lymphoma M Bewarder, M Kiefer, C Moelle, L Goerens, S Stilgenbauer, ... Frontiers in Oncology 10, 580364, 2020 | 7 | 2020 |
| KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials D Kaddu-Mulindwa, B Altmann, S Robrecht, M Ziepert, E Regitz, E Tausch, ... The Lancet Haematology 9 (2), e133-e142, 2022 | 6 | 2022 |
| Radiation and Dose‐densification of R‐CHOP in Primary Mediastinal B‐cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial G Held, L Thurner, V Poeschel, G Ott, C Schmidt, K Christofyllakis, ... Hemasphere 7 (7), e917, 2023 | 5 | 2023 |
| Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report K Christofyllakis, AR Monteiro, O Cetin, IA Kos, A Greystoke, A Luciani Journal of Geriatric Oncology 13 (8), 1071-1083, 2022 | 5 | 2022 |
| IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study D Kaddu‐Mulindwa, L Keuser, V Lesan, J Rissland, S Smola, ... HIV medicine 23 (5), 564-569, 2022 | 4 | 2022 |
| Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial D Kaddu-Mulindwa, V Lesan, C Berdel, S Stilgenbauer, M Bewarder, ... Leukemia & Lymphoma 63 (2), 326-334, 2022 | 4 | 2022 |
| Advances in lymphoma molecular diagnostics IA Kos, L Thurner, JT Bittenbring, K Christofyllakis, D Kaddu-Mulindwa Diagnostics 11 (12), 2174, 2021 | 4 | 2021 |
